Abstracts tagged "gout"

Abstract Number: 333 • 2019 ACR/ARP Annual Meeting
Assessing the Relationship Between Gout and Return to Hemodialysis Among U.S. Renal Transplant Patients
Justin Li¹, David Yin ¹, Zheng Wang ¹, Mark Brigham ¹, Brian LaMoreaux ², Jeffrey Kent ², Megan Francis-Sedlak ², Richard Johnson ³, Nandini Hadker ¹ and Gavin Miyasato ¹, ¹Trinity Partners, Waltham, MA, ²Horizon Therapeutics plc, Lake Forest, IL, ³University of Colorado Denver, Aurora, CO
Background/Purpose: Although gout has been shown to be associated with poor renal outcomes among chronic kidney disease populations, this relationship is not well understood among…
Abstract Number: 356 • 2019 ACR/ARP Annual Meeting
Gout Flares Become Infrequent During a Treat-to-target Strategy over One Year: Data from the NOR-Gout Study
Till Uhlig¹, Lars Fridtjof Karoliussen ², Espen A Haavardsholm ², Tore Kvien ¹ and Hilde Hammer ², ¹Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, ²Diakonhjemmet hospital, Oslo, Norway
Background/Purpose: Urate lowering therapy (ULT) is expected to prevent new gout flares. Treat-to-target ULT is however often not performed, and more evidence on how often…
Abstract Number: 1235 • 2019 ACR/ARP Annual Meeting
Monthly Dosing of ImmTOR Tolerogenic Nanoparticles Combined with Pegylated Uricase (Pegadricase) Mitigates Formation of Anti-Drug Antibodies Resulting in Sustained Uricase Activity in Symptomatic Gout Patients
Wesley DeHaan¹, Alan Kivitz ², Rehan Azeem ¹, Horacio Plotkin ¹, Lloyd Johnston ¹, Takashi K. Kishimoto ¹, Justin Park ¹, Stephen Smolinski ¹ and Sheldon Leung ¹, ¹Selecta Biosciences, Watertown, MA, ²Altoona Center for Clinical Research, Duncansville, PA
Background/Purpose: Gout is caused by the deposition of monosodium urate (MSU) crystals in joints due to chronic hyperuricemia. Long term treatment focuses on reducing sUA…
Abstract Number: 2836 • 2019 ACR/ARP Annual Meeting
Do Serum Urate-associated Genetic Variants Differentially Contribute to Gout Risk According to Body Mass Index? Analysis of the UK Biobank
Vicky Tai¹, Ravi Narang ¹, Greg Gamble ¹, Lisa Stamp ², Tony Merriman ³ and Nicola Dalbeth ¹, ¹University of Auckland, Auckland, New Zealand, ²University of Otago, Christchurch, Christchurch, Canterbury, New Zealand, ³University of Otago, Birmingham, AL
Background/Purpose: Both serum urate-associated genetic variants and body mass index (BMI) are associated with gout risk. The aim of this study was to systematically examine…
Abstract Number: 334 • 2019 ACR/ARP Annual Meeting
The Role of a ‘Treat-to-Target’ Approach on Long-term Renal Outcomes in Patients with Gout
Woo-Joong Kim ¹, Jung-Soo Song¹ and Sang Tae Choi ¹, ¹Chung-Ang University College of Medicine, Seoul, Republic of Korea
Background/Purpose: Although gout is accompanied by the substantial burden of kidney disease, there is limited data to assess renal function as a therapeutic target. There…
Abstract Number: 358 • 2019 ACR/ARP Annual Meeting
Emergency Department Encounters in a Large US Payer Database: Tophaceous versus Non-tophaceous Gout Patients
Meron Mezgebe¹, Megan Francis-Sedlak ¹, Brian LaMoreaux ¹ and Robert Holt ¹, ¹Horizon Therapeutics plc, Lake Forest, IL
Background/Purpose: From 2006 to 2012, gout was the primary indication for ~0.2% of all emergency department visits for adults, as reported in the Nationwide Emergency…
Abstract Number: 1236 • 2019 ACR/ARP Annual Meeting
Subcutaneous or Oral Methotrexate Exposure and Response to Pegloticase in Uncontrolled Gout Patients in a Community Rheumatology Practice
John A. Albert¹, Tony Hosey ² and Brian LaMoreaux ², ¹Rheumatic Disease Center, Milwaukee, IL, ²Horizon Therapeutics plc, Lake Forest, IL
Background/Purpose: Pegloticase is an infused biologic for uncontrolled gout patients that is highly effective but can cause anti-drug antibodies that lead to a lack of…
Abstract Number: 2839 • 2019 ACR/ARP Annual Meeting
Association of a Gout Polygenic Risk Score with Disease Severity Phenotypes Amongst Caucasian Gout Patients in Three Independent Cohorts
Nicholas Sumpter¹, Tony Merriman ², Richard Reynolds ³, Abhishek Abhishek ⁴, Mariano Andrés ⁵, Nicola Dalbeth ⁶, Michael Doherty ⁴, Lennart Jacobsson ⁷, Matthijs Janssen ⁸, Tim Jansen ⁹, Leo Joosten ¹⁰, Meliha Kapetanovic ¹¹, Frédéric Lioté ¹², Hirotaka Matsuo ¹³, Geraldine McCarthy ¹⁴, Fernando Perez-Ruiz ¹⁵, Philip Riches ¹⁶, Pascal Richette ¹⁷, Edward Roddy ¹⁸, Blanka Stiburkova ¹⁹, Alex So ²⁰, Lisa Stamp ²¹, Anne-Kathrin Tausche ²², Rosa Torres-Jimenez ²³ and Till Uhlig ²⁴, ¹University of Otago, Birmingham, ²University of Otago, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham, ⁴The University of Nottingham, Nottingham, United Kingdom, ⁵Hospital General Universitario de Alicante, Alicante, Spain, ⁶University of Auckland, Auckland, New Zealand, ⁷Dept of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden,, Gothenburg, Sweden, ⁸Rijnstate Hospital, Arnhem, Netherlands, ⁹Viecuri MC, Venlo, Netherlands, ¹⁰Department of Internal Medicine and Radboud Institute for Molecular Life Sciences (RIMLS), Radboud University Medical Center, Nijmegen, Netherlands, ¹¹Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Section of Rheumatology, Lund and Malmö, Sweden, Lund, Sweden, ¹²Rheumatology Department, Lariboisiere Hospital, AP-HP, Paris, France, Paris, France, ¹³National Defense Medical College, Tokorozawa, Japan, ¹⁴University College Dublin, Dublin, Ireland, ¹⁵Hospital de Cruces, Vizcaya, Spain, ¹⁶The University of Edinburgh, Edinburgh, United Kingdom, ¹⁷Department of Rheumatology, AP-HP Lariboisiere Hospital, Paris, France, ¹⁸Research Institute for Primary Care and Health Sciences and Keele Clinical Trials Unit, Keele, United Kingdom, ¹⁹Institute of Rheumatology; Department of Pediatrics and Adolescent Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic, Prague, Czech Republic, ²⁰Universite de Lausanne, Lausanne, Switzerland, ²¹University of Otago, Christchurch, Christchurch, Canterbury, New Zealand, ²²Universitatsklinikum Dresden, Dresden, Germany, ²³Instituto de Investigación Sanitaria del Hospital Universitario La Paz, Madrid, Spain, ²⁴Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway
Background/Purpose: This study aimed to determine whether a polygenic risk score (PRS) based on gout-associated genetic variants is associated with gout disease severity phenotypes such…
Abstract Number: 335 • 2019 ACR/ARP Annual Meeting
Renal Transplant Complications in Patients with and Without Gout
Megan Francis-Sedlak¹, Brian LaMoreaux ¹ and Robert Holt ¹, ¹Horizon Therapeutics plc, Lake Forest, IL
Background/Purpose: Graft-related complications are among the most serious issues solid-organ transplant recipients and their healthcare teams face post-operatively. Gout is a known frequent co-morbidity in…
Abstract Number: 360 • 2019 ACR/ARP Annual Meeting
Colchicine Prophylaxis of Gout Flares When Commencing Allopurinol Is Very Cost Effective: A Health Economic Analysis
Philip Robinson¹, Nicola Dalbeth ² and Peter Donovan ³, ¹University of Queensland, Brisbane, Queensland, Australia, ²University of Auckland, Auckland, New Zealand, ³University of Queensland, HERSTON, Australia
Background/Purpose: Prophylaxis of acute gout flares when commencing urate lowering therapy is recommended by international guidelines. Whether this is a cost-effective intervention is currently unknown.…
Abstract Number: 1238 • 2019 ACR/ARP Annual Meeting
Monosodium Urate and Calcium Pyrophosphatecrystal-induced Interleukin 1 Production Depends on Glucose Uptake Through Glut1 Transporter
Félix Renaudin ¹, Laure Campillo-Gimenez ², Florence Castelli ³, François Fenaille ³, Aurélie Prignon ⁴, Christele Combes ⁵, Martine Cohen-Solal ¹, Frédéric Lioté ⁶ and Hang Korng Ea¹, ¹Université Paris, INSERM UMR1132 BIOSCAR, Paris, France, ²Université Paris, INSERM UMR1132 BIOSCAR, San Diego, ³CEA Paris-Saclay, Laboratoire d’Etudes du Métabolisme des Médicaments, Saclay, France, ⁴UMS28 Phénotypage du petit animal, Laboratoire d'Imagerie Moléculaire Positonique (LIMP), Sorbonne Univerity, Paris, France, ⁵CIRIMAT, Université de Toulouse, INPT,UPS,CNRS,ENSIACET, Toulouse, France, ⁶Rheumatology Department, Lariboisiere Hospital, AP-HP, Paris, France, Paris, France
Background/Purpose: Monosodium urate (MSU) andmonoclinic calcium pyrophosphate dihydrated(mCPPD)crystals are responsible for relapsing acute arthritis which is driven by interleukin 1β (IL-1β).IL-1βproductionrelies onNLRP3 inflammasome activationleading to…
Abstract Number: 2889 • 2019 ACR/ARP Annual Meeting
From a Potential Solution to Part of the Problem: Analysis of Spending and Price Trends for Brand-Name and Generic Colchicine and Other Gout Medications
Natalie McCormick¹, Zachary Wallace ², Chio Yokose ³, April Jorge ³, Chana Sacks ⁴, John Hsu ⁵ and Hyon K. Choi ³, ¹Massachusetts General Hospital and Harvard Medical School, Boston, MA, ²Massachusetts General Hospital, Boston, ³Massachusetts General Hospital, Boston, MA, ⁴Department of General Internal Medicine, Massachusetts General Hospital; Department of Medicine, Harvard Medical School, Boston, MA, ⁵Mongan Institute, Massachusetts General Hospital; Department of Health Care Policy, Harvard Medical School, Boston, MA
Background/Purpose: Gout affects >4 million US adults aged ≥ 65 years, but little is known about the scale and drivers of public spending on gout…
Abstract Number: 336 • 2019 ACR/ARP Annual Meeting
Treating Gout to Target Entails Renoprotective Effect in Patients with Moderate Chronic Kidney Disease
enrique Calvo-Aranda¹, Marta Novella-Navarro ², jOSE LUIS CABRERA-ALARCON ³, Francisco Aramburu ², Iustina Janta ⁴, Alejandro Prada-Ojeda ⁵, Luis Sala-Icardo ⁵, Maria del Carmen Ortega de la O ⁶, Cesar Diaz-Torne ⁷ and A. Urruticoechea-Arana ⁸, ¹Hospital Universitario Infanta Leonor, Madrid, Spain, ²Hospital Universitario HM Sanchinarro, madrid, Spain, ³Bioinformatica CNIC, madrid, Spain, ⁴Hospital General Universitario Gregorio Marañón, madrid, Spain, ⁵Hospital Universitario de Torrejon, madrid, Spain, ⁶Hospital Universitario Santa Elena, madrid, Spain, ⁷Hospital de la Santa Creu i Sant Pau, barcelona, Catalonia, Spain, ⁸HU Can Misses, Ibiza, Spain
Background/Purpose: Approximately 25% of patients with gouty arthritis suffer from chronic kidney disease (CKD). High serum uric acid (sUA) levels have been related to glomerular…
Abstract Number: 362 • 2019 ACR/ARP Annual Meeting
Methods to Efficiently Recruit Minority Patients with Gout for Clinic-Based Registries
Giovanni Adami¹, Giovanna Rosas ², Joshua Melnick ³, Jeffrey Foster ², Elizabeth Rahn ², Amy Mudano ⁴, Jeffrey Curtis ², Tony Merriman ⁵, S Louis Bridges ⁴ and Kenneth Saag ², ¹University of Verona, Verona, Italy, ²University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Birmimgham, AL, ⁴University of Alabama at Birmingham, Birmingham, ⁵University of Otago, Birmingham, AL
Background/Purpose: Gout is frequently misdiagnosed and/or miscoded, making approaches to identifying eligible patients for observational and interventional studies more challenging. Ethnic and racial minorities are…
Abstract Number: 1240 • 2019 ACR/ARP Annual Meeting
A Randomized, Phase 2 Study Evaluating the Efficacy and Safety of Anakinra in Difficult-To-Treat Acute Gouty Arthritis: The anaGO Study
Kenneth Saag¹, Alexander So ², Puja Khanna ³, Robert Keenan ⁴, Sven Ohlman ⁵, Torbjörn Kullenberg ⁵, Lisa Osterling Koskinen ⁵, Michael Pillinger ⁶ and Robert Terkeltaub ⁷, ¹University of Alabama at Birmingham, Birmingham, AL, ²Université de Lausanne, Lausanne, Switzerland, ³University of Michigan Medical School, Ann Arbor, ⁴Duke University School of Medicine, Durham, ⁵Sobi, Stockholm, Sweden, ⁶New York University School of Medicine, New York, ⁷San Diego VA/UCSD, San Diego, CA
Background/Purpose: In gout, urate crystals deposited in and around joints trigger episodes of acute arthritis, mediated by the proinflammatory cytokine IL-1β. In uncontrolled studies, the…

1
2
3
…
24
Next Page »